Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Landmark' data has revealed a popular weight loss medicine slashes the risk of heart attack, stroke or heart disease death ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...

People taking Zepbound, lost nearly 50% more weight than those using rival Wegovy in the first head-to-head study of the ...